• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于磨玻璃密度转录组分析的机器学习方法构建预测标志物,实现早期 LUAD 的准确分类并探索其免疫微环境。

A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.

机构信息

Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.

Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China.

出版信息

Front Immunol. 2022 May 26;13:872387. doi: 10.3389/fimmu.2022.872387. eCollection 2022.

DOI:10.3389/fimmu.2022.872387
PMID:35693786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9178173/
Abstract

Screening for early-stage lung cancer with low-dose computed tomography is recommended for high-risk populations; consequently, the incidence of pure ground-glass opacity (pGGO) is increasing. Ground-glass opacity (GGO) is considered the appearance of early lung cancer, and there remains an unmet clinical need to understand the pathology of small GGO (<1 cm in diameter). The objective of this study was to use the transcriptome profiling of pGGO specimens <1 cm in diameter to construct a pGGO-related gene risk signature to predict the prognosis of early-stage lung adenocarcinoma (LUAD) and explore the immune microenvironment of GGO. pGGO-related differentially expressed genes (DEGs) were screened to identify prognostic marker genes with two machine learning algorithms. A 15-gene risk signature was constructed from the DEGs that were shared between the algorithms. Risk scores were calculated using the regression coefficients for the pGGO-related DEGs. Patients with Stage I/II LUAD or Stage IA LUAD and high-risk scores had a worse prognosis than patients with low-risk scores. The prognosis of high-risk patients with Stage IA LUAD was almost identical to that of patients with Stage II LUAD, suggesting that treatment strategies for patients with Stage II LUAD may be beneficial in high-risk patients with Stage IA LUAD. pGGO-related DEGs were mainly enriched in immune-related pathways. Patients with high-risk scores and high tumor mutation burden had a worse prognosis and may benefit from immunotherapy. A nomogram was constructed to facilitate the clinical application of the 15-gene risk signature. Receiver operating characteristic curves and decision curve analysis validated the predictive ability of the nomogram in patients with Stage I LUAD in the TCGA-LUAD cohort and GEO datasets.

摘要

低剂量计算机断层扫描(CT)筛查用于高危人群的早期肺癌;因此,纯磨玻璃密度(pGGO)的发病率正在增加。磨玻璃密度(GGO)被认为是肺癌的早期表现,目前仍需要了解小 GGO(直径<1 厘米)的病理学。本研究的目的是使用 pGGO 标本<1 厘米的转录组谱构建 pGGO 相关基因风险特征,以预测早期肺腺癌(LUAD)的预后,并探索 GGO 的免疫微环境。使用两种机器学习算法筛选 pGGO 相关差异表达基因(DEGs)以鉴定预后标志物基因。从算法之间共享的 DEGs 构建了一个 15 个基因风险特征。使用 pGGO 相关 DEGs 的回归系数计算风险评分。I/II 期 LUAD 或 IA 期 LUAD 和高风险评分的患者比低风险评分的患者预后更差。IA 期 LUAD 高危患者的预后几乎与 II 期 LUAD 患者相同,这表明 II 期 LUAD 患者的治疗策略可能对 IA 期 LUAD 高危患者有益。pGGO 相关 DEGs 主要富集在免疫相关途径中。高风险评分和高肿瘤突变负担的患者预后更差,可能受益于免疫治疗。构建了一个列线图,以促进 15 个基因风险特征在 TCGA-LUAD 队列和 GEO 数据集的 I 期 LUAD 患者中的临床应用。ROC 曲线和决策曲线分析验证了列线图在 TCGA-LUAD 队列和 GEO 数据集的 I 期 LUAD 患者中的预测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/277a5bd1e253/fimmu-13-872387-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/13d0a7a6a980/fimmu-13-872387-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/7cd78a7efb1a/fimmu-13-872387-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/a2555b368f97/fimmu-13-872387-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/459b9f9ecffb/fimmu-13-872387-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/9cde48d808e5/fimmu-13-872387-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/277a5bd1e253/fimmu-13-872387-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/13d0a7a6a980/fimmu-13-872387-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/7cd78a7efb1a/fimmu-13-872387-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/a2555b368f97/fimmu-13-872387-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/459b9f9ecffb/fimmu-13-872387-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/9cde48d808e5/fimmu-13-872387-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f77/9178173/277a5bd1e253/fimmu-13-872387-g006.jpg

相似文献

1
A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.基于磨玻璃密度转录组分析的机器学习方法构建预测标志物,实现早期 LUAD 的准确分类并探索其免疫微环境。
Front Immunol. 2022 May 26;13:872387. doi: 10.3389/fimmu.2022.872387. eCollection 2022.
2
Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.肿瘤突变负荷与免疫浸润联合用于肺腺癌的预后评估。
Int Immunopharmacol. 2021 Sep;98:107807. doi: 10.1016/j.intimp.2021.107807. Epub 2021 Jun 25.
3
Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.早期肺腺癌中一种稳健的免疫相关预后标志物的开发与验证
J Transl Med. 2020 Oct 7;18(1):380. doi: 10.1186/s12967-020-02545-z.
4
Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.基于 13 种程序性细胞死亡模式的机器学习对肺腺癌患者预后和治疗反应预测的分子亚型。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11351-11368. doi: 10.1007/s00432-023-05000-w. Epub 2023 Jun 28.
5
Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.早期肺腺癌中与临床结局相关的免疫景观和新型免疫治疗相关基因特征。
J Mol Med (Berl). 2020 Jun;98(6):805-818. doi: 10.1007/s00109-020-01908-9. Epub 2020 Apr 25.
6
Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.早期肺腺癌中与 TP53 相关的免疫景观和有前途的免疫预后模型。
Cancer Med. 2021 Feb;10(3):806-823. doi: 10.1002/cam4.3655. Epub 2020 Dec 12.
7
A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.一种与淋巴管侵犯相关的新型转录组特征可预测肺腺癌的临床结局、肿瘤微环境及治疗反应。
Int Immunopharmacol. 2024 Jan 25;127:111286. doi: 10.1016/j.intimp.2023.111286. Epub 2023 Dec 7.
8
Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.肺腺癌和肺鳞状细胞癌中免疫相关基因特征的鉴定
Front Immunol. 2021 Nov 23;12:752643. doi: 10.3389/fimmu.2021.752643. eCollection 2021.
9
Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.单细胞测序分析和转录组分析构建了肺腺癌中与巨噬细胞相关基因相关的特征,并通过独立队列进行了验证。
Genomics. 2022 Nov;114(6):110520. doi: 10.1016/j.ygeno.2022.110520. Epub 2022 Nov 11.
10
Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.肺腺癌中基于五个免疫检查点基因(IL(R))的表达signature 的临床意义和免疫图谱
Front Immunol. 2021 Aug 23;12:693062. doi: 10.3389/fimmu.2021.693062. eCollection 2021.

引用本文的文献

1
Artificial intelligence in lung cancer: current applications, future perspectives, and challenges.人工智能在肺癌中的应用:当前应用、未来展望及挑战
Front Oncol. 2024 Dec 23;14:1486310. doi: 10.3389/fonc.2024.1486310. eCollection 2024.
2
Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.肺部癌前进展:非小细胞肺癌干预的知识空白和新机遇。美国胸科学会官方研究声明。
Am J Respir Crit Care Med. 2024 Sep 1;210(5):548-571. doi: 10.1164/rccm.202406-1168ST.
3
Unravelling the diagnostic pathology and molecular biomarkers in lung cancer.

本文引用的文献

1
FAIM2 Promotes Non-Small Cell Lung Cancer Cell Growth and Bone Metastasis by Activating the Wnt/β-Catenin Pathway.FAIM2通过激活Wnt/β-连环蛋白信号通路促进非小细胞肺癌细胞生长和骨转移。
Front Oncol. 2021 Sep 9;11:690142. doi: 10.3389/fonc.2021.690142. eCollection 2021.
2
Clinicopathological value of long non-coding RNA profiles in gastrointestinal stromal tumor.长链非编码RNA谱在胃肠道间质瘤中的临床病理价值
PeerJ. 2021 Sep 3;9:e11946. doi: 10.7717/peerj.11946. eCollection 2021.
3
Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity.
解析肺癌的诊断病理学和分子生物标志物。
Breathe (Sheff). 2024 Jul 16;20(2):230192. doi: 10.1183/20734735.0192-2023. eCollection 2024 Jun.
4
The artificial intelligence and machine learning in lung cancer immunotherapy.人工智能和机器学习在肺癌免疫治疗中的应用。
J Hematol Oncol. 2023 May 24;16(1):55. doi: 10.1186/s13045-023-01456-y.
多组学分析揭示了具有磨玻璃密度的肺癌的独特免疫基因组特征。
Am J Respir Crit Care Med. 2021 Nov 15;204(10):1180-1192. doi: 10.1164/rccm.202101-0119OC.
4
Interfacing Seurat with the R tidy universe.与 R tidyverse 接口的 Seurat。
Bioinformatics. 2021 Nov 18;37(22):4100-4107. doi: 10.1093/bioinformatics/btab404.
5
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.NCCN 指南解读:非小细胞肺癌,第 2.2021 版。
J Natl Compr Canc Netw. 2021 Mar 2;19(3):254-266. doi: 10.6004/jnccn.2021.0013.
6
Comparison of Support Vector Machine, Naïve Bayes and Logistic Regression for Assessing the Necessity for Coronary Angiography.支持向量机、朴素贝叶斯和逻辑回归在评估冠状动脉造影必要性中的比较。
Int J Environ Res Public Health. 2020 Sep 4;17(18):6449. doi: 10.3390/ijerph17186449.
7
Clinical characteristics of resected solitary ground-glass opacities: Comparison between benign and malignant nodules.切除孤立性磨玻璃密度结节的临床特征:良性和恶性结节的比较。
Thorac Cancer. 2020 Oct;11(10):2767-2774. doi: 10.1111/1759-7714.13575. Epub 2020 Aug 25.
8
N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients.N6-甲基腺苷相关长链非编码RNA是预测低级别胶质瘤患者总生存期的潜在生物标志物。
Front Cell Dev Biol. 2020 Jul 23;8:642. doi: 10.3389/fcell.2020.00642. eCollection 2020.
9
A compendium of mutational cancer driver genes.癌症驱动基因突变综合分析
Nat Rev Cancer. 2020 Oct;20(10):555-572. doi: 10.1038/s41568-020-0290-x. Epub 2020 Aug 10.
10
Management of Ground-Glass Opacities in the Lung Cancer Spectrum.肺癌谱中磨玻璃密度影的管理。
Ann Thorac Surg. 2020 Dec;110(6):1796-1804. doi: 10.1016/j.athoracsur.2020.04.094. Epub 2020 Jun 7.